Gadolinium-based Contrast Agents: New Insights & Patient Recommendations
Tuesday, November 14, 2017 - Saturday, September 1, 2018
CME Provider:
ICPME › Linda McLean 33 Thornwood Drive Suite 400 Ithaca, New York (NY) 14850 United States
Phone: 607-257-5860 Fax: 607-257-5891
Visit the CME Provider Webpage ›
Description:
Course Overview and Educational Objectives
Data regarding gadolinium deposition in patients who have undergone contrast-enhanced MRI are rapidly evolving. Further research is needed to evaluate the clinical significance, if any, of these findings. In the meantime, radiologists and referring physicians must ensure informed decision-making about the benefits and potential risks to patients undergoing a contrast-enhanced MRI examination.
This lecture will discuss the relevant physicochemical properties and classification of gadolinium-based contrast agents, review recent literature on the deposition of gadolinium, and discuss recent changes to the ACR recommendations for screening patients undergoing GBCA examinations.
After completing this activity, the participants should be better able to:
Describe how physicochemical properties and classification of GBCAs may affect patient safety Discuss recent studies reporting the discovery of gadolinium deposits in patients who have undergone contrast-enhanced MRI exams Summarize what is known and not known regarding the clinical significance of gadolinium deposition in patients Implement new ACR screening guidelines for patients receiving a GBCA-enhanced procedure
Visit the CME Course Webpage ›
Instructors:
Jeffrey C. Weinreb, MD, FACR and Robert Lenkinski, PhD
CME Credit:
Physicians: 1.0 Hours
Radiologic Technologists: 1.0 Hours
Self Assessment Module (SAM):
Yes
Specialty Audience:
Radiology
RADLIST Course #17603
|
|
|